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Study of a Cohort of 1,886 Persons To Determine Changes in
Antibody Reactivity to Borrelia burgdorferi 3 Months after a Tick Bite
Ram B. Dessau,a Linda Fryland,b Peter Wilhelmsson,c Christina Ekerfelt,d Dag Nyman,e Pia Forsberg,b,f Per-Eric Lindgrenc
Department of Clinical Microbiology, Slagelse Hospital, Region Zealand, Slagelse, Denmarka; Infectious Medicine, Department of Clinical and Experimental Medicine,
Linköping University, Linköping, Swedenb; Medical Microbiology, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Swedenc; Clinical
Immunology, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Swedend; Åland Borrelia Group, Åland University of Applied Sciences,
Mariehamn, Finlande; Clinic of Infectious Diseases, University Hospital, Linköping, Swedenf
Lyme borreliosis is a tick-borne disease caused by the bacterium Borrelia burgdorferi. The most frequent clinical manifestation
is a rash called erythemamigrans. Changes in antibody reactivity to B. burgdorferi 3 months after a tick bite are measured using
enzyme-linked immunosorbent assays (ELISAs). One assay is based on native purified flagellum antigen (IgG), and the other
assay is based on a recombinant antigen called C6 (IgG or IgM). Paired samples were taken at the time of a tick bite and 3months
later from 1,886 persons in Sweden and the Åland Islands, Finland. The seroconversion or relative change is defined by dividing
the measurement units from the second sample by those from the first sample. The threshold for the minimum level of signifi-
cant change was defined at the 2.5% level to represent the random error level. The thresholds were a 2.7-fold rise for the flagellar
IgG assay and a 1.8-fold rise for the C6 assay. Of 1,886 persons, 102/101 (5.4%) had a significant rise in antibody reactivity in the
flagellar assay or the C6 assay. Among 40 cases with a diagnosis of Lyme borreliosis, the sensitivities corresponding to a rise in
antibodies were 33% and 50% for the flagellar antigen and the C6 antigen, respectively. Graphical methods to display the anti-
body response and to choose thresholds for a rise in relative antibody reactivity are shown and discussed. In conclusion, 5.4% of
people with tick bites showed a rise in Borrelia-specific antibodies above the 2.5% threshold in either ELISA but only 40 (2.1%)
developed clinical Lyme borreliosis.
Borrelia burgdorferi sensu lato is transmitted by hard ticks (Ix-odes ricinus or Ixodes persulcatus) throughout Europe, espe-
cially in the temperate climate zone. Both the vector and the bac-
terium are prevalent in southern Scandinavia, and ticks frequently
attach to humans and occasionally transmit B. burgdorferi (1–4).
Lyme borreliosis (LB) is also common in parts of the United
States. The term B. burgdorferi sensu lato denotes a species com-
plex belonging to the genus Borrelia and is herein designated sim-
ply B. burgdorferi or Borrelia. The most frequent species infecting
humans in Europe are B. afzelii, B. garinii, and B. burgdorferi sensu
stricto. In the United States, the only prevalent species is B. burg-
dorferi sensu stricto. The infections may involve the nervous sys-
tem, the skin, the joints, and the heart. The most frequent mani-
festation is a characteristic skin lesion called erythema migrans
(EM).
This study was based on data from the tick-borne diseases
(TBD) STING study (www.stingstudien.se). Ticks that had bitten
humans in the Åland Islands, Finland, and different parts of Swe-
den were collected and analyzed at Linköping University (2–5).
The focus of this study was to analyze the differences in the mea-
surements of B. burgdorferi-specific antibodies in the paired sam-
ples and propose methods for detecting changes in antibody reac-
tivity. Although the concept of antigen-induced stimulation and
seroconversion has broad application in diagnostic medicine, ep-
idemiology, and vaccine studies, methodological studies on how
to evaluate the paired samples from each individual and establish
decision thresholds have been scarce. The focus of interest is on
detecting a rise in antibody reactivity indicative of antigen stimu-
lation. The usual cutoff values based on interindividual variation
with “positive” or “negative” classification are not optimal for
comparisons of samples from the same individual. This large col-
lection of systematically retrieved material, with paired samples
collected 3 months apart from members of a tick-exposed popu-
lation, provides a unique opportunity to analyze and set standards
for changes in antibody reactivity.
MATERIALS AND METHODS
Materials. Serological samples and data collected from 1,886 persons in
the TBD STING study bitten by one or more ticks from 2007 to 2009 were
analyzed (2–5). A total of 394 of these participants were also described
previously (3). The participants had blood samples taken at the time of the
tick bite and 3 months later. Concerning the diagnosis of LB, if the par-
ticipants had visited a health care provider during the 3-month study
period, the medical record was obtained and scrutinized in detail by phy-
sicians with extensive clinical experience of LB and other tick-borne in-
fections (6). Diagnostic criteria were according to European guidelines (7,
8). Samples were stored frozen at70°C until they were analyzed.
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Data from 1,886 cases were available. Among the patients represented
by the cases, 668 (35%) were men and the median age was 63 years (range,
19 to 92 years). Forty (2.1%) people with tick bites were diagnosed with LB
(39 certain cases and 1 possible case) in the interval between the collection
of the first sample and the collection of the second sample. Of these, 34
were diagnosed with EM, 2 with unspecified LB, 1 with borrelial lympho-
cytoma, and 2 with neuroborreliosis, the latter 2 being both antibody
index positive and positive for pleocytosis in the spinal fluid. The patient
in one case had facial palsy, but no lumbar puncture was performed, so
this case did not have a certain diagnosis of LB. This patient (male, 60 years
old) had high levels of antibody in both assays, with a nonsignificant level
of relative change (RC). All 40 cases were used in the subsequent analysis.
All 40 patients diagnosed with LB received routine antibiotic treatment.
Assays. The samples were analyzed with native purified IgG flagellar
antigen (IDEIA; Oxoid, United Kingdom) and C6 (B. burgdorferi Lyme
enzyme-linked immunosorbent assay [ELISA]; Immunetics, Boston, MA,
USA). The C6 assay is based on a recombinant invariable fragment of the
VlsE antigen. The C6 assay does not distinguish between IgG and IgM
antibodies. Both assays have been described in previous publications from
Scandinavian studies (9–19). The C6 assay was implemented on a Bio-Rad
Coda microplate processor, and the IDEIA ELISA was performed manu-
ally. Paired samples were analyzed in the same ELISA plates.
Methods. Calibrated units were calculated as the optical density (OD)
of the sample divided by that of the calibrator for both the flagellar IgG
and C6 assays. For both assays, the RC was defined as the unit value for the
second sample taken 3 months after the tick bite divided by the unit value
for first sample taken at the time of the tick bite as follows: unit value 
OD of sample/OD of calibrator; RC unit value for sample 2/unit value
for sample 1.
Thus, the calibrator was normalized at a value of 1 and the RC was
close to a value of 1 for the cases in which there was no change in antibody
reactivity at 3 months. In this manner, it was possible to analyze and
exploit the full range of measurements, and the units used in this study
were not calculated as specified by the manufacturer of the assays. Using
the “normal” decision threshold with a simple negative or positive inter-
pretation may also detect false “seroconversion” due to simple random
variation in two nearly identical measurements close to the cutoff value.
The setting of thresholds for changes in antibody reactivity was developed
in this study.
Statistics.All statistical analyses and graphics were performed with the
freely available R statistical software (20). Implementation of the statisti-
cal methods was part of the study, and details of the methods are explained
in the relevant sections of Results. Statistical significance was defined as
observations exceeding the 2.5% threshold. Further details are provided
in the supplemental material.
RESULTS
Background seroreactivity. Using the routinely specified cutoff
values, 212 (11%) and 732 (39%) samples gave positive results in
the flagellar IgG and C6 assays, respectively, indicating high back-
ground immunity. Looking at the distribution of units (Fig. 1),
there is an obvious difference between the two assays. The native
flagellar antigen gives a left tail with a decreasing frequency of
cases with high values (Fig. 1A). The C6 assay shows a marked
bimodal distribution with a cluster of high unit values. However,
the cutoff value for the C6 assay is placed within the distribution of
the low-reactivity samples, which explains the high background
seropositivity (Fig. 1B).
Change in antibody reactivity 3months after a tick bite. Scat-
ter plots with sample 1 data on the x axis and sample 2 data on the
y axis show many points scattered along the diagonal where the x
values and the y values are equal (Fig. 2). This shows that most
persons do not develop a rise (or fall) in antibody reactivity after a
tick bite and that, in general, antibody measurements in the same
individual are reproducible, even when samples are measured 3
months apart (Fig. 2). The cases with a rise in reactivity in the
second sample are scattered in the upper left part of Fig. 2. Those
are the main targets of interest in this study. To show the statistical
distribution, upper and lower percentiles are shown together with
the 40 patients who developed LB between sample 1 and sample 2
collected 3 months later. There are some cases which showed a fall
in antibody reactivity (gray color), and these data represent either
random measurement variations or a faster downregulation of the
antibody response in a few individuals. Downregulation could
have been the case, especially with the C6 assay, for a few individ-
uals who had very high values in the first sample (gray circles in the
lower right part of Fig. 2). This was probably true, as these outliers
were not seen among the low-measurement values and thus were
present only in individuals with some reactivity in the first sample.
Note that none of the 40 LB cases had a fall in antibody reactivity
and that the reactivity data for many remained the same.
The changes in Borrelia-specific antibody reactivity in the same
individual in the two assays were compared using the RC value
(defined as the value from the second sample divided by the value
from the first sample) (Fig. 3). The pattern shows that most of the
reactive samples tended to show increased antibody reactivity in
both assays. Data corresponding to samples with low reactivity in
the second sample were removed from Fig. 3, except for the four
cases diagnosed with LB. These lower measurement values were
considered to be “truly” nonreactive without an increase in reac-
tivity and were thus filtered out. The values of 0.1 and 1.5 for the
flagellar and C6 assays, respectively, were chosen by visual inspec-
tion of Fig. 2 to rule out larger RCs in very low measurement
values (“low-level noise”) and at the same time to include some LB
cases with a lower degree of reactivity. A total of 331 cases, includ-
ing three LB cases, were nonreactive in both assays by this defini-
tion (see Fig. S1 in the supplemental material).
A receiver operating characteristic (ROC) curve (Fig. 4) was
constructed to assess if RC values determined using two samples
would be more accurate for diagnosis of erythema migrans than
the use of the data from single sample 2 alone. RC was significantly
more specific up to a sensitivity of 60%. Concerning RC, the C6
assay appears to have been slightly more specific than the flagellar
IgG assay but only at around a sensitivity of 40%.
How to determine a threshold value for a significant rise in
antibody reactivity.Different methods of establishing a threshold
for RC were considered.
FIG 1 Histograms of the distribution of units of the first sample (ln, natural
logarithm). (A) The flagellar IgG assay. (B) The C6 assay. The cutoff values are
indicated by vertical broken lines. The cutoff value for the flagellar assay is
equal to the calibrator value; thus, ln (1.1) 0.1. For the C6 assay, the calibra-
tor has a very low value, and the diagnostic cutoff value is at a higher level as a
consequence of adding a fixed value of 0.3. The resulting value is around 1.4 on
the logarithmic scale.
Dessau et al.
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(i) Use of the upper percentiles of RC as done for Fig. 2. As the
distribution is skewed due to the rises in the antibody reactivity
that we actually want to detect, this approach may be considered
too conservative.
(ii) Use of the ROC curve (Fig. 4) based on LB cases (mainly
EM). However, the ROC determined using the clinical diagnosis
for classification excludes the subclinical antibody stimulation af-
ter the tick bite, which we also want to characterize. Thus, possible
increases in antibody reactivity are considered controls.
(iii) Possible use of the mirror-symmetrical value of 2.5% from
the lower percentile (Fig. 2, gray points), assuming that this rep-
resents random error and is a symmetrical phenomenon. The
lower percentiles for RC are thus assumed to represent measure-
ment errors and variations in samples collected from the same
individual on two occasions 3 months apart. We also assume that
the natural logarithmic transformed measurements have similar
RC values for all reactivity levels along the diagonal line of identity
(Fig. 2). This is not strictly the case due to low- and high-level
limits in the measurement range, and outliers appear mostly in the
middle parts of Fig. 2A and B and in the lower part of panel 2A.
Therefore, the 2.5% lower-percentile value was chosen as a
threshold to represent the random error of measurement (see also
Fig. S2 in the supplemental material). The thresholds were 2.7 for
the flagellar IgG assay and 1.8 for the C6 assay. Using these thresh-
FIG 2 Results determined for the first sample collected when the tick was detected and for the second collected 3 months later for the flagellar IgG (A) and C6
(B) assays. The optical density reading of each sample was divided by the cutoff value. To indicate a statistically significant rise in seroreactivity, the values above
95% of the RC in seroreactivity are indicated with colored circles. Data from patients diagnosed with EM or other manifestations of LB are shown with larger solid
points. All very low measurements below 0.1 and 1.5 for the second sample for the flagellar IgG and C6 assays, respectively, are recorded as representing no
change. The scales are logarithmically transformed (base ln).
FIG 3 The RC over 3 months in seroreactivity for the flagellar IgG and C6
assays plotted to show coreactivity. A total of 40 patients with LB and 1,518
tick-bitten cases of patients without LB are plotted. Data from 328 non-LB
cases with very low absolute measurements below 0.1 and 1.5 in the second
sample for the flagellar IgG and C6 assays, respectively, have been removed.
FIG 4 ROC curve of data from the 40 cases of patients with LB compared to
people with tick bites without LB as controls. For the RC determinations, the
data from the 331 cases of patients with very low values have been removed.
The C6 curve based on RC is shown with 95% bootstrapped confidence inter-
vals. The sensitivities and specificities corresponding to RC thresholds of 2.7
for the flagellar IgG assay and 1.8 for the C6 assays are shown as black and red
dots, respectively. The second serum samples alone have a low discriminatory
power.
To Seroconvert or Not
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olds, of 1,886 people with tick bite, 102 and 101 (5.4%), respec-
tively, were classified as having a significant rise in antibody reac-
tivity for each assay separately. A total of 59 (3.1%) had a rise in
that value in the flagellar assay, 58 (3.1%) had a rise in that value in
the C6 assay, and 43 (2.3%) had a rise in that value in both assays.
Of the 40 cases diagnosed with LB, two (5%) had a titer rise in the
flagellar IgG assay only, 9 (23%) had a rise in the C6 assay only,
and 22 (11%) had a rise in both assays. Thus, the rates of titer rises
in the remaining 1,846 cases without LB were 89/1,846 (4.9%) and
81/1,846 (4.4%) for the two assays, respectively (see also Fig. S1 in
the supplemental material).
DISCUSSION
Relative change (also called “fold rise”) determinations and plot-
ting of the pre- and post-antibody responses on a logarithmic scale
(Fig. 2) have been used in vaccine studies (21). These types of
logarithmic plots have the advantage of displaying both the orig-
inal measurements and the RC as a straight line parallel to the
diagonal no-response (x  y) line. In addition, as shown in this
study, a threshold for a rise in antibody reactivity may be set using
the percentiles, which appears biologically plausible as judged
from Fig. 2. Thresholds may be set in various ways, but the use of
the percentile does not involve the assumption that underlying
(parametric) distributions and a symmetric standard deviation
would be inappropriate. More-complex models could be used,
but they involve more complexity and assumptions about the
shape of the underlying distributions (22, 23). In our case, we
would have two assays with different distributional profiles need-
ing separate modeling. A second low-reactivity-level threshold is
also chosen to filter out large RCs when the absolute measure-
ments are small. The choice of thresholds in this study was based
on the distribution of measurements. Percentiles were chosen be-
cause of the skewed distribution of RC, as a regression line would
assume symmetrical standard deviations from the straight line.
Thus, the maximal analytical capacity of the assays to detect
change is used. In this case, there is no independent standard on
which to base the thresholds for a titer rise as we may not know in
which of the 1,886 tick-bitten persons a true immune stimulation
did occur. Vaccine studies are different, as such studies represent
an experimental design in which researchers control the timing
and dose of exposure and may include a control group. It would
have been possible to investigate a control group for this study to
assess the base level of variation in antibody reactivity. This could
be represented by paired samples collected 3 months apart during
winter months, where the risk of tick exposure should be negligi-
ble. However, it may be noted that the standard deviation deter-
mined from the distribution of persons without change would be
unlikely to be very much different from that determined in the
present study, where the vast majority (90%) of persons had
nearly the same result in both samples. Thus, such an approach
would probably not have an important effect on the choice of
threshold anyway. Of course, this gives further information con-
cerning the specificity at the chosen threshold. Another control
group could consist of a random draw of persons from the same
geographical area during the same season without recognized tick
bites. However, as many tick bites go unnoticed, this group would
likely have similar exposure probabilities. Therefore, the approach
used to set thresholds in this study is probably the most pragmatic
and best choice. We cannot draw exact conclusions from this
study about how many of the statistically significant titer rises are
indicative of a true (subclinical) exposure to B. burgdorferi or of a
non-Borrelia cross-reacting stimulus. However, as Borrelia IgG
appears quite specific in other populations, such as blood donor
controls or patients suspected of Lyme arthritis, the majority of
significant increases in seroreactivity should be indicative of en-
demic exposure to B. burgdorferi resulting in a (subclinical) infec-
tion. In Europe, asymptomatic infections in exposed populations
are considered quite frequent (24–28). This is in contrast to the
results seen with the recombinant C6 antigen, which had a bi-
modal distribution, meaning that there was a “positive” group of
cases with strong binding of the antigen and a separate “negative”
group with low-level reactivity in the test system. The native fla-
gellar antigen is a more complex and larger molecule from cul-
tured Borrelia bacteria which probably has several binding sites
with some biological variability. The C6 assay has a high back-
ground seroreactivity level of 39%, and, due to the bimodal dis-
tributions, it would not help much to raise the cutoff value. It is
very interesting that the native flagellar antigen has much lower
reactivity in general but has the same ability to detect a rise in
antibody reactivity. The flagellar antigen data have larger variabil-
ity around the no-change diagonal in Fig. 2A, and a higher thresh-
old was needed at a 2.7-fold rise than at a 1.8-fold rise in the C6
assay. Nevertheless, the flagellar antigen had higher specificity in
this endemic population in analysis of the single first sample. Con-
cerning the C6 assay, a high rate of seropositivity in both blood
donors and consecutive routine specimens has been reported pre-
viously (13, 29). The flagellar IgG assay and the C6 assays were
chosen because they were routinely used by the laboratories in the
region. A separate IgM assay was not chosen, as this was consid-
ered to give a high nonspecific background, and has not been used
for clinical routine diagnosis in the local diagnostic laboratories.
Immunoblotting was not performed, as this has not been used
routinely in the region. A Western blot or immunoblot confirma-
tion is not a requirement in Sweden. In a future project, it would
be interesting to investigate changes in patterns of reactivity to
multiple different antigens. Methods to model changes in reactiv-
ity patterns are complex and need to be developed. Perhaps a
multiplex assay giving quantitative results and using a score based
on generalized linear modeling should be considered (30).
In our study, 40 (2.1%) study subjects developed LB, which is
higher (95% confidence interval [CI], 0.01% to 0.28%) than the
rate determined in a previous report on a subset of the same study
population, where none of the 394 study subjects developed LB
(3). However, the message, i.e., that the risk of LB after a tick bite
remains low and that testing for Borrelia-specific antibodies is not
relevant after a tick bite, remains the same. Also, in patients with
EM, the diagnosis is clinical, as the sensitivity of serology for de-
terminations of both increased antibody levels in a single sample
and a rise in antibody levels in paired samples is low.
The ROC curve shows that paired samples, if available, repre-
sent a better diagnostic marker than a single first sample alone.
However, in the normal clinical situations, the samples are rarely
taken before the development of disease. In conclusion, 5.4% of
people with tick bites developed a rise in the level of Borrelia-
specific antibodies above the 2.5% threshold in one of the two
ELISAs, but only 40 (2.1%) developed clinical LB. For diagnostic
purposes, a 2-fold to 3-fold or greater rise in antibody reactivity
may be considered a sign of Borrelia-specific immune stimulation.
Dessau et al.
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